Vicki Nienaber, Ph.D. Email and Phone Number

XplorStem is a science education company founded in 2019 with a National Science Foundation grant to democratize access to science education. Learning is guided through an online learning platform including a hands-on laboratory that reproduces historic scientific discoveries. The program is designed to be completed at home by homeschool students and does not require a science teacher in the room. Safety is a primary consideration and classic experiments have been reimagined and redesigned without harsh, caustic reagents. Art and creative writing activities are included to reinforce learning and all math required to understand and analyze laboratory data is taught.

Zenobia Fragments is the products division of Zenobia Therapeutics. It was launched in 2013 to accommodate the growing product line originally developed to support Zenobia Therapeutics research. Zenobia Fragments currently sells a fragment library collection of 960 compounds designed to be stand-alone and with high core diversity to yield a variety of hits. The collection is divided into four libraries, each with their own unique properties. A core library collection of 288 compounds that samples the entire collection is also available as an ideal, economical initial screen expected to yield quality hits and give an idea of the hit-rate expected from the full collection.Zenobia Fragments is currently growing into the field of protein stabilization during purification and crystallization using fragments of biological molecules and natural products. This serves as an alternative to glycerol and detergents which can be detrimental in biophysical measurements.

Zenobia Therapeutics is dedicated to curing diseases through collaborations with outstanding scientists and organizations, as well as with our own internal drug discovery programs. We use state-of-the-art technologies and continually optimize our methods to ensure rapid identification and optimization of fragment hits into small molecule inhibitors. Although our technology is independent of therapeutic area, we have chosen to focus on neurological and muscular degenerative diseases for our internal programs.